Tiziana Life Sciences (Nasdaq:TLSA) - Stock Price, News & Analysis

Resumen acción TLSA

Tiziana Life Sciences Ltd, empresa de biotecnología, se centra en el descubrimiento y desarrollo de moléculas para tratar enfermedades humanas en oncología e inmunología.

Acerca de la empresa

TLSA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 17.4% al año en los últimos 5 años

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

No tiene una capitalización bursátil significativa ($61M)

Competidores de Tiziana Life Sciences Ltd

MAIA Biotechnology

NYSEAM:MAIA

US$44.1m

ProMIS Neurosciences

NasdaqCM:PMN

US$43.4m

Viracta Therapeutics

NasdaqGS:VIRX

US$45.2m

SAB Biotherapeutics

NasdaqCM:SABS

US$43.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Tiziana Life Sciences
Historical stock prices
Current Share Price	US$0.44
52 Week High	US$1.39
52 Week Low	US$0.41
Beta	0.23
1 Month Change	-11.95%
3 Month Change	-22.87%
1 Year Change	-58.88%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-70.67%

Noticias y actualizaciones recientes

Recent updates

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

Rentabilidad de los accionistas

	TLSA	US Biotechs	Mercado US
7D	-2.4%	-2.8%	-1.7%
1Y	-58.9%	-0.2%	22.4%

Rentabilidad vs. Industria: TLSA obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 6%.

Rentabilidad vs. Mercado: TLSA obtuvo unos resultados inferiores a los del mercado US, que fue del 14.1% el año pasado.

Volatilidad de los precios

Is TLSA's price volatile compared to industry and market?
TLSA volatility
TLSA Average Weekly Movement	7.3%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: TLSAha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TLSA (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1998	9	Gabriele Marco Cerrone	www.tizianalifesciences.com

Tiziana Life Sciences Ltd, empresa biotecnológica, se dedica al descubrimiento y desarrollo de moléculas para el tratamiento de enfermedades humanas en oncología e inmunología. El principal producto candidato de la empresa en inmunología es Foralumab (TZLS-401), un anticuerpo monoclonal (mAb) humano anti-CD3 para el tratamiento de las enfermedades de Crohn, injerto contra huésped, colitis ulcerosa, esclerosis múltiple, diabetes de tipo 1, inflamación intestinal, psoriasis y artritis reumatoide. También desarrolla Milciclib (TZLS-201), una pequeña molécula inhibidora de varias quinasas dependientes de ciclinas, quinasas receptoras de tropomicina y quinasas de la familia Src que controlan el crecimiento celular y la progresión maligna del cáncer; y mAb antirreceptor (IL6R) (TZLS-501), un anticuerpo monoclonal totalmente humano para el tratamiento de la inflamación inducida por IL6 y para tratar a pacientes con COVID-19.

Resumen de fundamentos de Tiziana Life Sciences Ltd

¿Cómo se comparan los beneficios e ingresos de Tiziana Life Sciences con su capitalización de mercado?
Estadísticas fundamentales de TLSA
Capitalización bursátil	US$44.14m
Beneficios(TTM)	-US$19.50m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-2.3x

Ratio precio-beneficio (PE)

¿Está TLSA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TLSA
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$19.50m
Beneficios	-US$19.50m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.19
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado TLSA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción TLSA

Recompensas

Análisis de riesgos

Competidores de Tiziana Life Sciences Ltd

NYSEAM:MAIA

US$44.1m

NasdaqCM:PMN

US$43.4m

NasdaqGS:VIRX

US$45.2m

NasdaqCM:SABS

US$43.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Recent updates

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)

Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

New major risk - Share price stability

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study

Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022

Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects

Less than half of directors are independent

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana chief medical officer further increases holdings in company

Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index

Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences discloses share purchase by executive chairman

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer

Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Less than half of directors are independent

Tiziana Life Sciences Announces FDA Grants Permission to Enroll Up to 8 Additional Secondary Progressive Multiple Sclerosis Patients in the Expanded Access Program with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, Fully Human Anti-Cd3 Monoclonal Antibody, in Patients with Crohn’s Disease

Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces an Equity Buyback for $5 million worth of its shares.

Tiziana Life Sciences PLC Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

Less than half of directors are independent

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Tiziana Life Sciences Ltd

0.0x

-2.3x